Cellceutix Provides Additional Insight into Successful Phase 2 Trial for Treating Psoriasis
May 26, 2016 | Press Releases
Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
May 24, 2016 | Press Releases
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
May 11, 2016 | Press Releases
Cellceutix Institutes “Database Soft Lock” on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
April 19, 2016 | Press Releases
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
March 31, 2016 | Press Releases
Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis
March 30, 2016 | Press Releases
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
March 17, 2016 | Press Releases
Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
March 8, 2016 | Press Releases
Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Top-Line Data Anticipated in May
March 1, 2016 | Press Releases
